It is in front of an audience of 3500 experts that Servier made its show Sunday in Chicago at the great world congress on cancer of Asco (American Society of Clinical Oncology). The French laboratory, which was one of the few elected in plenary, presented the positive phase 3 results - the last step before the application for registration - of Vorasidenib. It is a treatment for the most common brain cancer, glioma, with a specific genetic mutation (GHI).
Studies show that this treatment reduces the progression of the tumour by 61%, i.e. the time until the next procedure. In addition, it is a targeted therapy, which targets malignant cells, less harmful to the body than conventional treatments (chemotherapy, radiotherapy). If this drug does not definitively cure this type of tumor (2300 new cases per year in the United States), it allows an improvement in life expectancy while there was previously no ...
This article is for subscribers only. You still have 81% to discover.
Want to read more?
Unblock all items immediately.
TEST FOR 0,99€
Already a subscriber? Log
